Saracatinib (AZD0530)
中文名称：塞卡替尼
Saracatinib (AZD0530)是一种有效的Src抑制剂，无细胞试验中IC50为2.7 nM，对c-Yes， Fyn， Lyn， Blk， Fgr和Lck也具有活性；但对Abl和EGFR (L858R和L861Q)活性较低。Saracatinib可诱导自噬。Phase 2/3。
Saracatinib (AZD0530) Chemical Structure
CAS: 379231-04-6
客户使用Selleck的Saracatinib (AZD0530)发表文献273篇
产品质控
批次：
纯度：
99.99%
99.99
Saracatinib (AZD0530)相关产品
| 相关靶点 | Lck Fyn Lyn Yes Fgr | 点击展开 |
|---|---|---|
| 相关产品 | Bosutinib PP2 Tirbanibulin SU6656 PP1 WH-4-023 Src Inhibitor 1 RK 24466 Myristic Acid eCF506 Tolimidone (MLR-1023) Src Rabbit Recombinant mAb UM-164 | 点击展开 |
| 相关化合物库 | 酪氨酸激酶抑制剂分子库 PI3K/Akt 抑制剂库 血管生成相关化合物库 HIF-1信号通路化合物库 FDA抗癌药物库 | 点击展开 |
相关信号通路图
Src抑制剂选择性比较
细胞实验数据示例
| 细胞系 | 实验类型 | 给药浓度 | 孵育时间 | 活性描述 | 文献信息 |
|---|---|---|---|---|---|
| Huh7 | Antiviral assay | 2.5 uM | 5 days | Inhibition of viral spread in Dengue virus-infected human Huh7 cells assessed as accumulation of viral envelope protein within perinuclear region at 2.5 uM after 5 days by immunofluorescence assay relative to control | 17360676 |
| Huh7 | Antiviral assay | 2.5 uM | 6 days | Inhibition of viral spread in Dengue virus-infected human Huh7 cells assessed as accumulation of viral envelope protein within perinuclear region at 2.5 uM after 6 days by immunofluorescence assay relative to control | 17360676 |
| Vero | Antiviral assay | 2.5 uM | 4 days | Inhibition of viral spread in Dengue virus-infected african green monkey Vero cells assessed as accumulation of viral envelope protein within perinuclear region at 2.5 uM after 4 days by immunofluorescence assay relative to control | 17360676 |
| Vero | Antiviral assay | 2.5 uM | 6 days | Inhibition of viral spread in Dengue virus-infected african green monkey Vero cells assessed as accumulation of viral envelope protein within perinuclear region at 2.5 uM after 6 days by immunofluorescence assay relative to control | 17360676 |
| C6/36 | Antiviral assay | 2.5 uM | 4 days | Inhibition of viral spread in Dengue virus-infected asian tiger mosquito C6/36 cells assessed as accumulation of viral envelope protein within perinuclear region at 2.5 uM after 4 days by immunofluorescence assay relative to control | 17360676 |
| C6/36 | Antiviral assay | 2.5 uM | 5 days | Inhibition of viral spread in Dengue virus-infected asian tiger mosquito C6/36 cells assessed as accumulation of viral envelope protein within perinuclear region at 2.5 uM after 5 days by immunofluorescence assay relative to control | 17360676 |
| Vero | Antiviral assay | 2.5 uM | 5 days | Inhibition of viral spread in Dengue virus-infected african green monkey Vero cells assessed as accumulation of viral envelope protein within perinuclear region at 2.5 uM after 5 days by immunofluorescence assay relative to control | 17360676 |
| Huh7 | Antiviral assay | 2.5 uM | 4 days | Inhibition of viral spread in Dengue virus-infected human Huh7 cells assessed as accumulation of viral envelope protein within perinuclear region at 2.5 uM after 4 days by immunofluorescence assay relative to control | 17360676 |
| C6/36 | Antiviral assay | 2.5 uM | 6 days | Inhibition of viral spread in Dengue virus-infected asian tiger mosquito C6/36 cells assessed as accumulation of viral envelope protein within perinuclear region at 2.5 uM after 6 days by immunofluorescence assay relative to control | 17360676 |
| HEK293 | Function assay | 0.1 to 1 uM | 16 hrs | Inhibition of collagen I-induced DDR2 (unknown origin) phosphorylation expressed in HEK293 cells at 0.1 to 1 uM after 16 hrs by Western blotting | 26191369 |
| HEK293 | Function assay | 0.1 to 1 uM | 16 hrs | Inhibition of collagen I-induced DDR2 I638F mutant (unknown origin) phosphorylation expressed in HEK293 cells at 0.1 to 1 uM after 16 hrs by Western blotting | 26191369 |
| HEK293 | Function assay | 1 hr | Inhibition of human full length PKMYT1 expressed in HEK293 cells using EFS (247 to 259 residues) as substrate after 1 hr by fluorescence polarization immunoasay, Ki = 0.0398 μM. | 29941193 | |
| HEK293 | Function assay | 1 hr | Inhibition of human full length PKMYT1 expressed in HEK293 cells using EFS (247 to 259 residues) as substrate after 1 hr by fluorescence polarization immunoasay, IC50 = 0.418 μM. | 29941193 | |
| Rh30 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human Rh30 cells after 48 hrs by CellTiter-Glo luminescent assay, IC50 = 10.1 μM. | 23787099 | |
| Vero | Antiviral assay | 3 days | Antiviral activity against Dengue virus infected in african green monkey Vero cells administered after viral challenge after 3 days by viral plaque assay | 17360676 | |
| SH-4 | Growth Inhibition Assay | IC50=4.25259 μM | SANGER | ||
| PF-382 | Growth Inhibition Assay | IC50=3.83698 μM | SANGER | ||
| OVCAR-4 | Growth Inhibition Assay | IC50=3.73433 μM | SANGER | ||
| KNS-42 | Growth Inhibition Assay | IC50=3.65 μM | SANGER | ||
| LC-2-ad | Growth Inhibition Assay | IC50=3.557 μM | SANGER | ||
| SF126 | Growth Inhibition Assay | IC50=3.31174 μM | SANGER | ||
| ETK-1 | Growth Inhibition Assay | IC50=3.20767 μM | SANGER | ||
| LXF-289 | Growth Inhibition Assay | IC50=3.12109 μM | SANGER | ||
| KU812 | Growth Inhibition Assay | IC50=3.05299 μM | SANGER | ||
| GCIY | Growth Inhibition Assay | IC50=2.87005 μM | SANGER | ||
| IST-SL2 | Growth Inhibition Assay | IC50=2.72379 μM | SANGER | ||
| SNB75 | Growth Inhibition Assay | IC50=2.68594 μM | SANGER | ||
| SW954 | Growth Inhibition Assay | IC50=2.57408 μM | SANGER | ||
| BL-70 | Growth Inhibition Assay | IC50=2.47422 μM | SANGER | ||
| MSTO-211H | Growth Inhibition Assay | IC50=2.35723 μM | SANGER | ||
| MZ1-PC | Growth Inhibition Assay | IC50=2.29356 μM | SANGER | ||
| NCI-H747 | Growth Inhibition Assay | IC50=2.25714 μM | SANGER | ||
| SW872 | Growth Inhibition Assay | IC50=2.18507 μM | SANGER | ||
| SW962 | Growth Inhibition Assay | IC50=2.17178 μM | SANGER | ||
| GI-1 | Growth Inhibition Assay | IC50=2.16084 μM | SANGER | ||
| TGBC24TKB | Growth Inhibition Assay | IC50=2.05958 μM | SANGER | ||
| KALS-1 | Growth Inhibition Assay | IC50=1.98722 μM | SANGER | ||
| SW982 | Growth Inhibition Assay | IC50=1.92093 μM | SANGER | ||
| OS-RC-2 | Growth Inhibition Assay | IC50=1.88574 μM | SANGER | ||
| SK-N-DZ | Growth Inhibition Assay | IC50=1.84688 μM | SANGER | ||
| GB-1 | Growth Inhibition Assay | IC50=1.79833 μM | SANGER | ||
| MFH-ino | Growth Inhibition Assay | IC50=1.7787 μM | SANGER | ||
| DOHH-2 | Growth Inhibition Assay | IC50=1.71782 μM | SANGER | ||
| RL95-2 | Growth Inhibition Assay | IC50=1.66902 μM | SANGER | ||
| TE-10 | Growth Inhibition Assay | IC50=1.66252 μM | SANGER | ||
| LB1047-RCC | Growth Inhibition Assay | IC50=1.55453 μM | SANGER | ||
| EW-16 | Growth Inhibition Assay | IC50=1.55083 μM | SANGER | ||
| HOP-62 | Growth Inhibition Assay | IC50=1.50246 μM | SANGER | ||
| ST486 | Growth Inhibition Assay | IC50=1.45852 μM | SANGER | ||
| TE-1 | Growth Inhibition Assay | IC50=1.44105 μM | SANGER | ||
| TE-11 | Growth Inhibition Assay | IC50=1.43418 μM | SANGER | ||
| NB69 | Growth Inhibition Assay | IC50=1.37497 μM | SANGER | ||
| KGN | Growth Inhibition Assay | IC50=1.27687 μM | SANGER | ||
| RXF393 | Growth Inhibition Assay | IC50=1.2436 μM | SANGER | ||
| C2BBe1 | Growth Inhibition Assay | IC50=1.20507 μM | SANGER | ||
| KS-1 | Growth Inhibition Assay | IC50=1.19779 μM | SANGER | ||
| TK10 | Growth Inhibition Assay | IC50=0.90669 μM | SANGER | ||
| A704 | Growth Inhibition Assay | IC50=0.8921 μM | SANGER | ||
| TE-8 | Growth Inhibition Assay | IC50=0.87275 μM | SANGER | ||
| BB30-HNC | Growth Inhibition Assay | IC50=0.86203 μM | SANGER | ||
| NCI-H1436 | Growth Inhibition Assay | IC50=0.79049 μM | SANGER | ||
| NCCIT | Growth Inhibition Assay | IC50=0.73218 μM | SANGER | ||
| BV-173 | Growth Inhibition Assay | IC50=0.65249 μM | SANGER | ||
| EW-24 | Growth Inhibition Assay | IC50=0.62693 μM | SANGER | ||
| NOS-1 | Growth Inhibition Assay | IC50=0.60529 μM | SANGER | ||
| D-336MG | Growth Inhibition Assay | IC50=0.50304 μM | SANGER | ||
| K-562 | Growth Inhibition Assay | IC50=0.44967 μM | SANGER | ||
| LB996-RCC | Growth Inhibition Assay | IC50=0.44196 μM | SANGER | ||
| TE-12 | Growth Inhibition Assay | IC50=0.3268 μM | SANGER | ||
| NCI-H1648 | Growth Inhibition Assay | IC50=0.28116 μM | SANGER | ||
| TE-15 | Growth Inhibition Assay | IC50=0.27412 μM | SANGER | ||
| EM-2 | Growth Inhibition Assay | IC50=0.265 μM | SANGER | ||
| MEG-01 | Growth Inhibition Assay | IC50=0.23688 μM | SANGER | ||
| LAMA-84 | Growth Inhibition Assay | IC50=0.1599 μM | SANGER | ||
| CTV-1 | Growth Inhibition Assay | IC50=0.06143 μM | SANGER | ||
| KM12 | Growth Inhibition Assay | IC50=4.32416 μM | SANGER | ||
| NB5 | Growth Inhibition Assay | IC50=4.41864 μM | SANGER | ||
| KURAMOCHI | Growth Inhibition Assay | IC50=4.65256 μM | SANGER | ||
| Becker | Growth Inhibition Assay | IC50=4.66416 μM | SANGER | ||
| MV-4-11 | Growth Inhibition Assay | IC50=4.81344 μM | SANGER | ||
| KINGS-1 | Growth Inhibition Assay | IC50=4.82373 μM | SANGER | ||
| LS-123 | Growth Inhibition Assay | IC50=5.49684 μM | SANGER | ||
| SF268 | Growth Inhibition Assay | IC50=5.61262 μM | SANGER | ||
| A388 | Growth Inhibition Assay | IC50=5.63667 μM | SANGER | ||
| NMC-G1 | Growth Inhibition Assay | IC50=6.01811 μM | SANGER | ||
| CGTH-W-1 | Growth Inhibition Assay | IC50=6.02075 μM | SANGER | ||
| ES4 | Growth Inhibition Assay | IC50=6.53074 μM | SANGER | ||
| SR | Growth Inhibition Assay | IC50=6.58807 μM | SANGER | ||
| BB49-HNC | Growth Inhibition Assay | IC50=6.73206 μM | SANGER | ||
| KLE | Growth Inhibition Assay | IC50=6.78377 μM | SANGER | ||
| HUTU-80 | Growth Inhibition Assay | IC50=6.98466 μM | SANGER | ||
| SNU-C2B | Growth Inhibition Assay | IC50=7.82737 μM | SANGER | ||
| BB65-RCC | Growth Inhibition Assay | IC50=7.94904 μM | SANGER | ||
| QIMR-WIL | Growth Inhibition Assay | IC50=8.42808 μM | SANGER | ||
| GDM-1 | Growth Inhibition Assay | IC50=8.97292 μM | SANGER | ||
| LC4-1 | Growth Inhibition Assay | IC50=9.00911 μM | SANGER | ||
| MLMA | Growth Inhibition Assay | IC50=9.15006 μM | SANGER | ||
| EoL-1-cell | Growth Inhibition Assay | IC50=9.30192 μM | SANGER | ||
| BOKU | Growth Inhibition Assay | IC50=9.96466 μM | SANGER | ||
| EVSA-T | Growth Inhibition Assay | IC50=10.6568 μM | SANGER | ||
| D-283MED | Growth Inhibition Assay | IC50=10.9176 μM | SANGER | ||
| NB1 | Growth Inhibition Assay | IC50=11.0242 μM | SANGER | ||
| RPMI-8402 | Growth Inhibition Assay | IC50=11.178 μM | SANGER | ||
| NCI-H1355 | Growth Inhibition Assay | IC50=11.1806 μM | SANGER | ||
| NB7 | Growth Inhibition Assay | IC50=11.3297 μM | SANGER | ||
| RPMI-6666 | Growth Inhibition Assay | IC50=12.9567 μM | SANGER | ||
| 697 | Growth Inhibition Assay | IC50=13.2701 μM | SANGER | ||
| CTB-1 | Growth Inhibition Assay | IC50=13.5948 μM | SANGER | ||
| VA-ES-BJ | Growth Inhibition Assay | IC50=13.9234 μM | SANGER | ||
| BE-13 | Growth Inhibition Assay | IC50=14.3915 μM | SANGER | ||
| SKM-1 | Growth Inhibition Assay | IC50=14.4499 μM | SANGER | ||
| TE-6 | Growth Inhibition Assay | IC50=14.7591 μM | SANGER | ||
| LB771-HNC | Growth Inhibition Assay | IC50=14.7898 μM | SANGER | ||
| ECC4 | Growth Inhibition Assay | IC50=17.0277 μM | SANGER | ||
| ES3 | Growth Inhibition Assay | IC50=17.4655 μM | SANGER | ||
| LB647-SCLC | Growth Inhibition Assay | IC50=17.4949 μM | SANGER | ||
| NB10 | Growth Inhibition Assay | IC50=18.5256 μM | SANGER | ||
| L-540 | Growth Inhibition Assay | IC50=18.8109 μM | SANGER | ||
| NCI-H2126 | Growth Inhibition Assay | IC50=19.51 μM | SANGER | ||
| HH | Growth Inhibition Assay | IC50=20.0099 μM | SANGER | ||
| MPP-89 | Growth Inhibition Assay | IC50=23.2289 μM | SANGER | ||
| IST-MEL1 | Growth Inhibition Assay | IC50=23.8658 μM | SANGER | ||
| KP-N-YS | Growth Inhibition Assay | IC50=23.9255 μM | SANGER | ||
| EC-GI-10 | Growth Inhibition Assay | IC50=24.5989 μM | SANGER | ||
| EKVX | Growth Inhibition Assay | IC50=26.0203 μM | SANGER | ||
| TGBC1TKB | Growth Inhibition Assay | IC50=26.434 μM | SANGER | ||
| Daudi | Growth Inhibition Assay | IC50=27.0773 μM | SANGER | ||
| ALL-PO | Growth Inhibition Assay | IC50=27.081 μM | SANGER | ||
| NB6 | Growth Inhibition Assay | IC50=27.488 μM | SANGER | ||
| ES6 | Growth Inhibition Assay | IC50=27.9123 μM | SANGER | ||
| COLO-320-HSR | Growth Inhibition Assay | IC50=28.0373 μM | SANGER | ||
| K5 | Growth Inhibition Assay | IC50=28.1287 μM | SANGER | ||
| ES1 | Growth Inhibition Assay | IC50=28.7773 μM | SANGER | ||
| LC-1F | Growth Inhibition Assay | IC50=29.7346 μM | SANGER | ||
| SCLC-21H | Growth Inhibition Assay | IC50=30.7317 μM | SANGER | ||
| SK-PN-DW | Growth Inhibition Assay | IC50=32.5598 μM | SANGER | ||
| D-247MG | Growth Inhibition Assay | IC50=32.9773 μM | SANGER | ||
| TE-5 | Growth Inhibition Assay | IC50=33.0362 μM | SANGER | ||
| MONO-MAC-6 | Growth Inhibition Assay | IC50=33.5048 μM | SANGER | ||
| LB2518-MEL | Growth Inhibition Assay | IC50=33.7666 μM | SANGER | ||
| LOXIMVI | Growth Inhibition Assay | IC50=33.7928 μM | SANGER | ||
| NCI-H209 | Growth Inhibition Assay | IC50=35.144 μM | SANGER | ||
| A253 | Growth Inhibition Assay | IC50=35.7429 μM | SANGER | ||
| HCC1599 | Growth Inhibition Assay | IC50=36.7053 μM | SANGER | ||
| EB-3 | Growth Inhibition Assay | IC50=36.9518 μM | SANGER | ||
| GOTO | Growth Inhibition Assay | IC50=37.3224 μM | SANGER | ||
| SW684 | Growth Inhibition Assay | IC50=41.8495 μM | SANGER | ||
| DEL | Growth Inhibition Assay | IC50=42.0522 μM | SANGER | ||
| HT-144 | Growth Inhibition Assay | IC50=42.1676 μM | SANGER | ||
| TE-9 | Growth Inhibition Assay | IC50=43.4596 μM | SANGER | ||
| KARPAS-45 | Growth Inhibition Assay | IC50=44.3925 μM | SANGER | ||
| HAL-01 | Growth Inhibition Assay | IC50=44.5034 μM | SANGER | ||
| RCC10RGB | Growth Inhibition Assay | IC50=44.7392 μM | SANGER | ||
| CP67-MEL | Growth Inhibition Assay | IC50=45.6241 μM | SANGER | ||
| NB17 | Growth Inhibition Assay | IC50=45.6643 μM | SANGER | ||
| SK-UT-1 | Growth Inhibition Assay | IC50=45.9464 μM | SANGER | ||
| JiyoyeP-2003 | Growth Inhibition Assay | IC50=46.0119 μM | SANGER | ||
| HCE-4 | Growth Inhibition Assay | IC50=46.5968 μM | SANGER | ||
| NCI-H720 | Growth Inhibition Assay | IC50=46.7682 μM | SANGER | ||
| KARPAS-422 | Growth Inhibition Assay | IC50=47.0895 μM | SANGER | ||
| Ramos-2G6-4C10 | Growth Inhibition Assay | IC50=47.1622 μM | SANGER | ||
| HCE-T | Growth Inhibition Assay | IC50=47.6828 μM | SANGER | ||
| PSN1 | Growth Inhibition Assay | IC50=47.7813 μM | SANGER | ||
| NIH3T3 | Function assay | Inhibition of human c-Src in NIH3T3 cells, IC50 = 0.0027 μM. | 17064066 | ||
| A673 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 29435139 | ||
| DAOY | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 29435139 | ||
| BT-37 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 29435139 | ||
| RD | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 29435139 | ||
| SK-N-SH | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 29435139 | ||
| OHS-50 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 29435139 | ||
| SJ-GBM2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 29435139 | ||
| SK-N-MC | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 29435139 | ||
| LAN-5 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 29435139 | ||
| 点击查看更多细胞系数据 | |||||
生物活性
| 产品描述 | Saracatinib (AZD0530)是一种有效的Src抑制剂，无细胞试验中IC50为2.7 nM，对c-Yes， Fyn， Lyn， Blk， Fgr和Lck也具有活性；但对Abl和EGFR (L858R和L861Q)活性较低。Saracatinib可诱导自噬。Phase 2/3。 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 特性 | Saracatinib是第一个作用于人类肿瘤组织Src通路的抑制剂。 | |||||||||||
| 靶点 |
|
| 体外研究(In Vitro) | ||||
| 体外研究活性 | Saracatinib也有效抑制其他Src酪氨酸激酶家族成员，包括c-Yes, Fyn, Lyn, Blk, Fgr, 和Lck，IC50为4到10 nM。Saracatinib有效抑制SrcY530F突变的NIH 3T3细胞，IC50为80 nM。在NBT-II膀胱癌细胞中，Saracatinib显著阻断HT1080细胞通过立体骨胶原基质的入侵，且完全抑制EGF诱导的细胞分散。[1]Saracatinib作用于DU145和PC3细胞，通过抑制Y419磷酸化而有效抑制Src激活。Saracatinib抑制前列腺癌包括PC3, DU145, CWR22Rv1和 LNCaP的生长，而Saracatinib作用于 LAPC-4, PZ-HPV7和RWPE-1细胞时却显示低活性。Saracatinib使细胞周期停止在G1/S期，但是不使caspase 3断裂。Saracatinib 也明显抑制Boyden 小室的DU145和PC3 移动。[2]Saracatinib有效且持久抑制Akt，且增强A549和Calu-6细胞对放射处理的敏感性。[3]Saracatinib在活性，再吸收，及组成上抑制蚀骨细胞。Saracatinib也可逆阻断蚀骨细胞前体的移动。[4] |
|||
|---|---|---|---|---|
| 激酶实验 | 激酶实验 | |||
| 使用受体和非受体酪氨酸激酶的重组催化区，通过酶联免疫吸附法测定酪氨酸激酶活性的IC50值。加入的Saracatinib剂量从0.001到10 mM不等。针对丝氨酸/苏氨酸激酶的特定实验是加32P 的渗透捕捉实验。在加入10 μL 20mM Mg.ATP开始反应前，包含0.5 μL Saracatinib或DMSO（作对照) 或pH 3.0 buffer（作对照）的多支路384孔板加入15 μL酶和肽/蛋白底物温育5分钟。 所有酶的最终浓度都接近米氏常数（Km）。实验在室温下进行30分钟，然后加入5 μL正磷酸终止反应。混合后，孔中的内含物加到P81联合板上，使用正磷酸作为洗涤缓冲液，然后计算IC50值。 | ||||
| 细胞实验 | 细胞系 | PC3, DU145, CWR22Rv1, LNCaP, LAPC-4, PZ-HPV7，和RWPE-1细胞 | ||
| 浓度 | 62.5 nM-16 mM | |||
| 孵育时间 | 1, 3，和5天 | |||
| 方法 | PC3, DU145, CWR22Rv1, LNCaP, LAPC-4, PZ-HPV7 及RWPE-1细胞按2×103密度接种在96孔板上，温育过夜。加入浓度不等（62.5 nM-16 mM）的Saracatinib。1,3,5天后分离培养基，每孔加入0.2 mL DMSO，按每分钟200轮持续震荡96孔板15分钟。MTT实验测IC50值。 |
|||
| 实验图片 | 检测方法 | 检测指标 | 实验图片 | PMID |
| Western blot | pY576-FAK / pY861-FAK / FAK pY418 Src / Src / pY410 CAS / CAS / Py421 Cortactin / Cortactin p-Akt / p-mTOR / Akt / mTOR / p-S6 / S6 / p-AMPKα / AMPKα |
|
20551056 | |
| Growth inhibition assay | Cell number |
|
24349321 | |
| 体内研究(In Vivo) | ||
| 体内研究活性 |
Saracatinib作用于Src3T3异体移植物显示出强的肿瘤生长抑制率，且Saracatinib造成Calu-6, MDA-MB-231, AsPc-1和BT474C移植瘤生长适当延迟。[1]Saracatinib处理常位DU145鼠，按鼠体重，每千克每天口服处理25mg Saracatinib，结果显示出强的抗癌活性。[2] |
|
|---|---|---|
| 动物实验 | Animal Models | 移植DU145细胞的CB17鼠 |
| Dosages | 25 mg/kg | |
| Administration | 每天口服处理 | |
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT04598919 | Recruiting | Idiopathic Pulmonary Fibrosis (IPF) |
National Jewish Health|Yale University|Icahn School of Medicine at Mount Sinai|AstraZeneca|National Center for Advancing Translational Sciences (NCATS)|Baylor University|International Center for Health Outcomes and Innovation Research |
November 12 2020 | Phase 1|Phase 2 |
| NCT04307953 | Recruiting | Fibrodysplasia Ossificans Progressiva |
Amsterdam UMC location VUmc|Royal National Orthopaedic Hospital NHS Trust|Klinikum Garmisch-Patenkirchen|University of Oxford|Brigham and Women''s Hospital|AstraZeneca|Innovative Medicines Initiative |
August 5 2020 | Phase 2 |
| NCT02085603 | Completed | Cancer |
Sheffield Teaching Hospitals NHS Foundation Trust|AstraZeneca |
March 2014 | Phase 2 |
| NCT01864655 | Completed | Alzheimer''s Disease |
Stephen M. Strittmatter|National Institute of Neurological Disorders and Stroke (NINDS)|Yale University |
July 2013 | Phase 1 |
| NCT01000896 | Withdrawn | Cancer|Non Small Cell Lung Cancer|Epithelial Ovarian Cancer |
AstraZeneca |
January 2010 | Phase 1 |
化学信息&溶解度
| 分子量 | 542.03 | 分子式 | C27H32ClN5O5 |
| CAS号 | 379231-04-6 | SDF | Download Saracatinib (AZD0530) SDF |
| Smiles | CN1CCN(CC1)CCOC2=CC3=C(C(=C2)OC4CCOCC4)C(=NC=N3)NC5=C(C=CC6=C5OCO6)Cl | ||
| 储存条件(自收到货起) | |||
|
体外溶解度 |
DMSO : 100 mg/mL ( (184.49 mM)； DMSO吸湿会降低化合物溶解度，请使用新开封DMSO) Ethanol : 100 mg/mL Water : Insoluble |
摩尔浓度计算器 |
|
体内溶解度 现配现用，请按从左到右的顺序依次添加，澄清后再加入下一溶剂 |
动物体内配方计算器 | ||||
实验计算
动物体内配方计算器（澄清溶液）
第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）
mg/kg
g
μL
只
第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）
% DMSO
%
% Tween 80
% ddH2O
%DMSO
%
计算结果：
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于μL DMSO溶液（母液浓度mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；
体内配方配制方法：取μL DMSO母液，加入μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入μL ddH2O，混匀澄清。
体内配方配制方法：取μL DMSO母液，加入μL Corn oil，混匀澄清。
注意：1. 首先保证母液是澄清的；
2.一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
技术支持
在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。
如果有其他问题，请给我们留言。
* 必填项
常见问题及建议解决方法
问题 1:
What is the half-life of Saracatinib?
回答：
Based on the following paper, the half-life of Saracatinib in vivo is around 40hours and it reaches its peak lever around 2-4 hours after dosing: http://clincancerres.aacrjournals.org/content/16/19/4876.long
Tags: buy Saracatinib (AZD0530) | Saracatinib (AZD0530) supplier | purchase Saracatinib (AZD0530) | Saracatinib (AZD0530) cost | Saracatinib (AZD0530) manufacturer | order Saracatinib (AZD0530) | Saracatinib (AZD0530) distributor
